Fidelity Investments’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$775K Buy
52,980
+4,859
+10% +$72K ﹤0.01% 3105
2026
Q1
$698K Buy
48,121
+14,913
+45% +$173K ﹤0.01% 2993
2025
Q4
$319K Buy
33,208
+12,461
+60% +$119K ﹤0.01% 3247
2025
Q3
$195K Sell
20,747
-8,328
-29% -$79.5K ﹤0.01% 3354
2025
Q2
$308K Buy
29,075
+2,829
+11% +$35.7K ﹤0.01% 3155
2025
Q1
$394K Sell
26,246
-710
-3% -$11.8K ﹤0.01% 2983
2024
Q4
$444K Buy
26,956
+2,235
+9% +$44.1K ﹤0.01% 2976
2024
Q3
$611K Buy
24,721
+4,996
+25% +$130K ﹤0.01% 2770
2024
Q2
$500K Buy
19,725
+5,075
+35% +$132K ﹤0.01% 2731
2024
Q1
$372K Buy
14,650
+3,165
+28% +$76.6K ﹤0.01% 2822
2023
Q4
$260K Sell
11,485
-1,790
-13% -$37K ﹤0.01% 2875
2023
Q3
$247K Sell
13,275
-3,230
-20% -$67K ﹤0.01% 2824
2023
Q2
$429K Buy
16,505
+200
+1% +$5.35K ﹤0.01% 2705
2023
Q1
$468K Sell
16,305
-68
-0.4% -$2.02K ﹤0.01% 2711
2022
Q4
$485K Sell
16,373
-114
-0.7% -$3.24K ﹤0.01% 2730
2022
Q3
$393K Sell
16,487
-883
-5% -$20.3K ﹤0.01% 2854
2022
Q2
$388K Buy
17,370
+4,500
+35% +$100K ﹤0.01% 2924
2022
Q1
$323K Buy
12,870
+12,794
+16,834% +$390K ﹤0.01% 3118
2021
Q4
$3K Sell
76
-6
-7% -$240 ﹤0.01% 3898
2021
Q3
$3K Hold
82
﹤0.01% 3892
2021
Q2
$4K Sell
82
-69
-46% -$2.94K ﹤0.01% 3751
2021
Q1
$6K Buy
151
+75
+99% +$2.85K ﹤0.01% 3492
2020
Q4
$3K Hold
76
﹤0.01% 3506
2020
Q3
$3K Sell
76
-3
-4% -$108 ﹤0.01% 3383
2020
Q2
$3K Sell
79
-80
-50% -$2.64K ﹤0.01% 3299
2020
Q1
$5K Sell
159
-215
-57% -$8.7K ﹤0.01% 3244
2019
Q4
$19K Buy
374
+169
+82% +$9.82K ﹤0.01% 3118
2019
Q3
$11K Sell
205
-48
-19% -$2.46K ﹤0.01% 3201
2019
Q2
$10K Buy
253
+91
+56% +$3.32K ﹤0.01% 3227
2019
Q1
$5K Buy
162
+21
+15% +$719 ﹤0.01% 3248
2018
Q4
$5K Sell
141
-73
-34% -$2.63K ﹤0.01% 3172
2018
Q3
$9K Buy
+214
New +$8.46K ﹤0.01% 3144
2017
Q1
Sell
-36,200
Closed -$1.77M 2642
2016
Q4
$1.77M Buy
+36,200
New +$1.67M ﹤0.01% 2394

Other funds holding ANIK

Fidelity Investments's ANIK Position: Q2 2026 in Review

Fidelity Investments increased its Anika Therapeutics (ANIK) stake by 10% in Q2 2026, buying an estimated $72K and bringing the position to 52,980 shares worth $775K. The position accounts for ﹤0.01% of the portfolio, ranked #3105.

Fidelity Investments first reported a position in ANIK in Q4 2016 and has held it in 33 quarters since. The position peaked at $1.77M in Q4 2016. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Fidelity Investments held 52,980 shares of Anika Therapeutics worth $775K as of Q2 2026.
  • Fidelity Investments bought 4,859 Anika Therapeutics shares in Q2 2026, an estimated $72K.
  • Anika Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3105 holding.
  • Fidelity Investments first reported a position in Anika Therapeutics in Q4 2016 and has held it in 33 quarters since.
  • Fidelity Investments's Anika Therapeutics position peaked at $1.77M in Q4 2016.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.